Overview

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
Stock Information
BOLD (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$20.77
Change (%) Stock is Down 1.33 (0.00%)
Volume67,284
Data as of 07/26/17 4:00 p.m. ET
Refresh quote
Stock chart for: BOLD.O.  Currently trading at $20.77 with a 52 week high of $22.82 and a 52 week low of $13.06.
Recent NewsMore >>
07/18/17
Audentes Therapeutics Announces Appointment of Fulvio Mavilio, Ph.D. to Vice President Scientific Affairs, Europe
06/28/17
Audentes Therapeutics Announces Participation in Upcoming Investor Conferences
06/13/17
Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
Upcoming EventsMore >>
Tuesday, August 15, 2017 12:45 p.m. ET
Audentes Therapeutics Inc at Wedbush PacGrow Healthcare Conference

Primary IR Contact
Thomas Soloway
SVP and Chief Financial Officer
Audentes Therapeutics, Inc.
E-mail: ir@audentestx.com

Data provided by Nasdaq. Minimum 15 minutes delayed.